Comparative Pharmacology
Head-to-head clinical analysis: AMOXIL versus CYCLAPEN W.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMOXIL versus CYCLAPEN W.
AMOXIL vs CYCLAPEN-W
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and activating autolytic enzymes, leading to bacterial lysis.
Cyclacillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has a similar spectrum to ampicillin but with increased acid stability and oral absorption.
250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours; for severe infections, up to 500 mg every 8 hours or 875 mg every 12 hours.
250-500 mg orally every 6 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections.
None Documented
None Documented
Terminal half-life: 1-1.5 hours (normal renal function); prolonged to 7-20 hours in anuria; neonates: 3-4 hours.
0.5-1 hour in adults with normal renal function; prolonged to 2-6 hours in renal impairment.
Renal: 60-80% unchanged via tubular secretion and glomerular filtration; Biliary/fecal: minor, <5% excreted in bile; dose adjustment in CrCl <30 mL/min.
Primarily renal (90-100% unchanged via glomerular filtration and tubular secretion); minor biliary/fecal elimination (<10%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic